Skip to main content

Table 3 Prevalence of the metabolic syndrome in specific age ranges

From: Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study

 

Prevalence

 

NCEP 2004

n = 156

NCEP 2001

n = 149

WHO

n = 70

IDF

n = 159

EGIR

n = 47

Age < 40 years n (%)

2 (0.5)

2 (0.5)

2 (0.6)

3 (0.9)

0 (0)

Age 40 to 49 years n (%)

12 (3.1)

12 (3.1)

4 (1.1)

12 (3.4)

0 (0)

Age 50 to 59 years n (%)

32 (8.2)

29 (7.5)

15 (4.2)

32 (9.1)

12 (3.1)

Age ≥ 60 years n (%)

110 (28.3)

106 (27.2)

49 (13.6)

112 (31.9)

35 (9.0)

  1. EGIR = European Group for Insulin Resistance; IDF = International Diabetes Federation; NCEP = National Cholesterol Education Programme; WHO = World Health Organization.
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us